{"id":"high-intensity-statin","safety":{"commonSideEffects":[{"rate":"1–5","effect":"Muscle pain or myalgia"},{"rate":"1–3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"1–2","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"}]},"_chembl":{"chemblId":"CHEMBL286958","moleculeType":"Small molecule","molecularWeight":"555.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Statins competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis. This leads to decreased intracellular cholesterol levels, upregulation of LDL receptors on hepatocytes, and increased clearance of LDL cholesterol from the bloodstream. High-intensity statins (such as atorvastatin and rosuvastatin) achieve greater LDL reduction compared to moderate-intensity agents.","oneSentence":"High-intensity statins inhibit HMG-CoA reductase to potently reduce LDL cholesterol synthesis in the liver.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:19.502Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary prevention of cardiovascular disease in high-risk patients"},{"name":"Secondary prevention of cardiovascular events in patients with established coronary artery disease"},{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":"Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia","enrollment":103},{"nctId":"NCT06975111","phase":"PHASE2, PHASE3","title":"Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-03-01","conditions":"Menopause, Menopause Hot Flashes, Menopause Related Conditions","enrollment":200},{"nctId":"NCT06488105","phase":"PHASE2","title":"Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-08-05","conditions":"Lipid Disorder, Hypercholesterolemia, Cardiovascular Diseases","enrollment":130},{"nctId":"NCT07440381","phase":"PHASE3","title":"triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE","status":"NOT_YET_RECRUITING","sponsor":"Heart Care Foundation","startDate":"2026-09","conditions":"Acute Coronary Syndromes, Secondary Prevention, Lipids","enrollment":600},{"nctId":"NCT06841536","phase":"NA","title":"Combined Effects of Statins and Exercise on Training Sensitive Health Markers","status":"COMPLETED","sponsor":"University of the Faroe Islands","startDate":"2025-05-01","conditions":"Dyslipidemias","enrollment":120},{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT06676280","phase":"PHASE4","title":"ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography","status":"RECRUITING","sponsor":"Jung-min Ahn","startDate":"2025-07-24","conditions":"Cardiovascular Diseases","enrollment":5000},{"nctId":"NCT05782777","phase":"NA","title":"Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-04-07","conditions":"Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation","enrollment":4310},{"nctId":"NCT06238466","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-01-16","conditions":"Cardiovascular","enrollment":96},{"nctId":"NCT07032389","phase":"PHASE2","title":"A Polypill for Acute Coronary Syndrome","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-12-05","conditions":"Acute Coronary Syndrome","enrollment":1000},{"nctId":"NCT06431763","phase":"PHASE4","title":"A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-06-21","conditions":"Hypercholesterolemia","enrollment":402},{"nctId":"NCT06782243","phase":"NA","title":"Comparison of High and Moderate Intensity Statins in Achieving the Target LDL-C Level After Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2024-12-20","conditions":"Acute Coronary Syndrome","enrollment":190},{"nctId":"NCT05579626","phase":"PHASE4","title":"Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)","status":"ENROLLING_BY_INVITATION","sponsor":"Seung-Whan Lee, M.D., Ph.D.","startDate":"2023-03-14","conditions":"Pre Diabetes, ASCVD","enrollment":4000},{"nctId":"NCT07307989","phase":"PHASE2","title":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-08-01","conditions":"Ischemic Stroke, Hypercholesteremia","enrollment":300},{"nctId":"NCT05537064","phase":"NA","title":"Centralized Prescribing for Statins","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-11-02","conditions":"Hyperlipidemias","enrollment":1950},{"nctId":"NCT07012629","phase":"PHASE3","title":"A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-26","conditions":"Covert Brain Infarction","enrollment":1652},{"nctId":"NCT04755413","phase":"NA","title":"The Precision CAD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-19","conditions":"Coronary Artery Disease","enrollment":276},{"nctId":"NCT05720156","phase":"","title":"Immunomodulatory Effects of PCSK9 Inhibition","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2024-04-04","conditions":"Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis","enrollment":""},{"nctId":"NCT06767345","phase":"PHASE4","title":"Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-05-12","conditions":"Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic","enrollment":408},{"nctId":"NCT06551701","phase":"","title":"ACHIEVE Pilot Statins for Vascular Protection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2025-05-19","conditions":"ASCVD","enrollment":225},{"nctId":"NCT06722521","phase":"PHASE4","title":"GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-09","conditions":"Primary Prevention, Vascular Calcification","enrollment":7435},{"nctId":"NCT07084259","phase":"PHASE4","title":"Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Hanyang University Seoul Hospital","startDate":"2025-07","conditions":"Coronary Artery Disease","enrollment":352},{"nctId":"NCT06564909","phase":"PHASE2","title":"Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-06-01","conditions":"Reperfusion Injury, Myocardial, Myocardial Infarction","enrollment":76},{"nctId":"NCT06681896","phase":"NA","title":"Microvascular Coronary Rehabilitation For Improving Treatment - Feasibility Study","status":"RECRUITING","sponsor":"Royal United Hospitals Bath NHS Foundation Trust","startDate":"2024-11-12","conditions":"Microvascular Coronary Dysfunction, Microvascular Angina, Coronary Microvascular Dysfunction (CMD)","enrollment":40},{"nctId":"NCT05457582","phase":"NA","title":"PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2023-03-30","conditions":"Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention","enrollment":1212},{"nctId":"NCT06767774","phase":"PHASE4","title":"Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-04-25","conditions":"ASCVD, Diabetes, Statin","enrollment":2000},{"nctId":"NCT05368545","phase":"NA","title":"Influence of Lipid Lowering on Impaired Coronary Flow","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2020-05-15","conditions":"Coronary Artery Disease","enrollment":109},{"nctId":"NCT04824911","phase":"PHASE2","title":"Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-03-23","conditions":"Acute Stroke, Dual Antiplatelet Therapy, Statin","enrollment":376},{"nctId":"NCT05001984","phase":"PHASE2","title":"Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-08-01","conditions":"Intracranial Atherosclerosis, Acute Ischemic Stroke, ICAS - Intracranial Atherosclerosis","enrollment":60},{"nctId":"NCT06604117","phase":"","title":"Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-17","conditions":"Ischemic Stroke, Atherosclerosis of Artery, Lipid Disorder","enrollment":200},{"nctId":"NCT06693934","phase":"NA","title":"Jockey Club Precision Prevention Programme on Young Onset Diabetes","status":"RECRUITING","sponsor":"Juliana CN Chan","startDate":"2024-11-23","conditions":"Diabetes, Pre Diabetes, Hypertension","enrollment":9000},{"nctId":"NCT06280976","phase":"PHASE4","title":"Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2024-03-01","conditions":"Coronary Artery Disease, Atherosclerosis, Heart Attack","enrollment":""},{"nctId":"NCT06413641","phase":"NA","title":"VIsualization of Coronary Artery Disease for Modification of RISK Factors","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2024-03-12","conditions":"Coronary Artery Disease, Non-Obstructive Coronary Atherosclerosis","enrollment":273},{"nctId":"NCT06784557","phase":"PHASE4","title":"Effect of Ezetimibe on Gut Microbiota","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-02-28","conditions":"Atherosclerotic Cardiovascular Disease With Dyslipidemia","enrollment":110},{"nctId":"NCT05845424","phase":"PHASE4","title":"High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2023-07-03","conditions":"Coronary Artery Calcification, Metabolic Syndrome, Dyslipidemias","enrollment":6000},{"nctId":"NCT05251129","phase":"NA","title":"Statin InTensity to Prevent Coronary Artery Vasculopathy After Heart Transplantation","status":"WITHDRAWN","sponsor":"Montefiore Medical Center","startDate":"2025-01","conditions":"Vasculopathy","enrollment":""},{"nctId":"NCT06588231","phase":"NA","title":"Effect of Individualized Exercise in Elderly Patients With Coronary Heart Disease","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-10-17","conditions":"Coronary Heart Disease","enrollment":200},{"nctId":"NCT05360602","phase":"NA","title":"Alpha Lipoic Acid Effect on No-Reflow Phenomenon","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":"No-Reflow Phenomenon","enrollment":70},{"nctId":"NCT03872388","phase":"PHASE2","title":"Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-23","conditions":"Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8","enrollment":6},{"nctId":"NCT04701242","phase":"NA","title":"Ezetimibe Utilization Early After Acute Myocardial Infarction, \"EzAMI Trial\"","status":"RECRUITING","sponsor":"Cairo University","startDate":"2021-03-24","conditions":"Acute Myocardial Infarction, Dyslipidemias","enrollment":500},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT04753606","phase":"PHASE2","title":"Randomized Study of Obicetrapib as an Adjunct to Statin Therapy","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2021-02-18","conditions":"Dyslipidemias, High Cholesterol, Hypercholesterolemia","enrollment":120},{"nctId":"NCT05266586","phase":"PHASE2","title":"Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2022-03-09","conditions":"Dyslipidemias, High Cholesterol, Hypercholesterolemia","enrollment":119},{"nctId":"NCT05742841","phase":"PHASE4","title":"EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-08","conditions":"Lipid Disorder","enrollment":22},{"nctId":"NCT05974345","phase":"","title":"In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-03","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":204691},{"nctId":"NCT06262685","phase":"PHASE4","title":"Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2024-03-04","conditions":"Cardiovascular Diseases, Dyslipidemias, Statin Adverse Reaction","enrollment":216},{"nctId":"NCT05166187","phase":"NA","title":"Best Practice Advisory to Initiate High-Intensity Statin Therapy in Patients With Peripheral Artery Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-20","conditions":"Peripheral Artery Disease","enrollment":152},{"nctId":"NCT03329599","phase":"PHASE2","title":"Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment","status":"COMPLETED","sponsor":"Northern California Institute of Research and Education","startDate":"2019-02-14","conditions":"Atherosclerosis, Adherence, Medication, Tolerance","enrollment":148},{"nctId":"NCT05976893","phase":"PHASE4","title":"Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer","status":"UNKNOWN","sponsor":"Xiang Xie","startDate":"2023-08-01","conditions":"ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor","enrollment":620},{"nctId":"NCT03635749","phase":"PHASE3","title":"Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2018-09-17","conditions":"Acute Stroke, Transient Ischemic Attack","enrollment":6100},{"nctId":"NCT05765370","phase":"NA","title":"LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-03-24","conditions":"Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol","enrollment":4200},{"nctId":"NCT05806723","phase":"PHASE4","title":"Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men","status":"COMPLETED","sponsor":"Hopital La Rabta","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Statin Adverse Reaction","enrollment":104},{"nctId":"NCT02579499","phase":"PHASE4","title":"Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2016-09-09","conditions":"Coronary Artery Diseasse","enrollment":4400},{"nctId":"NCT03570697","phase":"PHASE3","title":"Imaging of Coronary Plaques in Participants Treated With Evolocumab","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-11-19","conditions":"Coronary Artery Disease (CAD)","enrollment":164},{"nctId":"NCT05306990","phase":"NA","title":"Statins in Patients With Type 2 Diabetes Mellitus and Previous History of Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Helwan University","startDate":"2017-04-20","conditions":"Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Mellitus","enrollment":108},{"nctId":"NCT04631536","phase":"PHASE3","title":"Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC","status":"UNKNOWN","sponsor":"Lebanese American University Medical Center","startDate":"2021-01-10","conditions":"Covid19","enrollment":42},{"nctId":"NCT05081336","phase":"","title":"Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry","status":"UNKNOWN","sponsor":"University Clinical Centre of Republic of Srpska","startDate":"2021-03-01","conditions":"Acute Coronary Syndrome, Dyslipidemias","enrollment":500},{"nctId":"NCT02586155","phase":"PHASE3","title":"Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD","status":"COMPLETED","sponsor":"Resverlogix Corp","startDate":"2015-11","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":2425},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT04754789","phase":"PHASE3","title":"Effect of Upstream Treatment With High Intensity Statin on the Outcomes of STMI Patients Treated With PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-02-20","conditions":"ST Elevation Myocardial Infarction","enrollment":160},{"nctId":"NCT02634151","phase":"PHASE2","title":"A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins","status":"COMPLETED","sponsor":"NeuroBo Pharmaceuticals Inc.","startDate":"2016-11","conditions":"Hypercholesteremia","enrollment":105},{"nctId":"NCT04080310","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-03-15","conditions":"Cardiovascular Diseases","enrollment":270},{"nctId":"NCT04087200","phase":"","title":"Protective Effect of Early High Dose stATins On Cardiovascular and Renal Events in Acute Coronary Syndrome","status":"RECRUITING","sponsor":"Centro Cardiopatici Toscani","startDate":"2016-12-01","conditions":"Acute Coronary Syndrome","enrollment":2500},{"nctId":"NCT03625089","phase":"NA","title":"Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis","status":"WITHDRAWN","sponsor":"Chinese University of Hong Kong","startDate":"2018-09-01","conditions":"Arthritis, Rheumatoid, Arthritis, Psoriatic","enrollment":""},{"nctId":"NCT03044665","phase":"NA","title":"RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2017-03-15","conditions":"Cardiovascular Diseases, Cerebrovascular Disease, Peripheral Atherosclerotic Disease","enrollment":3780},{"nctId":"NCT02207634","phase":"PHASE3","title":"Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-09-10","conditions":"Dyslipidemia","enrollment":1974},{"nctId":"NCT03277079","phase":"PHASE4","title":"Low Dose Statins, Ezetimibe and Nutraceuticals","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2017-10-01","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT02001883","phase":"PHASE4","title":"Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2013-11","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":876,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"High-intensity statin","genericName":"High-intensity statin","companyName":"Jung-min Ahn","companyId":"jung-min-ahn","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-intensity statins inhibit HMG-CoA reductase to potently reduce LDL cholesterol synthesis in the liver. Used for Primary prevention of cardiovascular disease in high-risk patients, Secondary prevention of cardiovascular events in patients with established coronary artery disease, Hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}